TriVax-HPV: An improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

Kelly Barrios, Esteban Celis

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Background Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse eVects and in most cases are not eVective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is eVective in generating vast numbers of antigen-speciWc T cells in mice capable of persisting for long time periods. Materials and methods We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic eYcacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E749-57, mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. Results TriVax using HPV16-E749-57 induced large and persistent T-cell responses that were therapeutically eVective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6-11-day established tumors. In addition, TriVax induced long-Term immunological memory, which prevented tumor recurrences. The anti-Tumor eVects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon. Conclusions These Wndings indicate that the TriVax strategy is an appealing immunotherapeutic approach for the treatment of established viral-induced tumors. We believe that these studies may help to launch more eVective and less invasive therapeutic vaccines for HPV-mediated malignancies.

Original languageEnglish (US)
Pages (from-to)1307-1317
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Vaccination
Peptides
Neoplasms
Therapeutics
T-Lymphocytes
Immunologic Memory
Papillomavirus Vaccines
Cancer Vaccines
T-Lymphocyte Epitopes
Long-Term Memory
Viral Proteins
Autoimmunity
Interferon-gamma
Anti-Idiotypic Antibodies
Vaccines
Carcinoma
Phenotype
Antigens
Recurrence

Keywords

  • CD8 T cells
  • Cervical cancer
  • HPV
  • PIVAC 11
  • Peptide vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

TriVax-HPV : An improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. / Barrios, Kelly; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 8, 01.08.2012, p. 1307-1317.

Research output: Contribution to journalReview article

@article{d1db3a747ef94053a45745dd9a4f3234,
title = "TriVax-HPV: An improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers",
abstract = "Background Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse eVects and in most cases are not eVective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is eVective in generating vast numbers of antigen-speciWc T cells in mice capable of persisting for long time periods. Materials and methods We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic eYcacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E749-57, mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. Results TriVax using HPV16-E749-57 induced large and persistent T-cell responses that were therapeutically eVective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6-11-day established tumors. In addition, TriVax induced long-Term immunological memory, which prevented tumor recurrences. The anti-Tumor eVects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon. Conclusions These Wndings indicate that the TriVax strategy is an appealing immunotherapeutic approach for the treatment of established viral-induced tumors. We believe that these studies may help to launch more eVective and less invasive therapeutic vaccines for HPV-mediated malignancies.",
keywords = "CD8 T cells, Cervical cancer, HPV, PIVAC 11, Peptide vaccines",
author = "Kelly Barrios and Esteban Celis",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s00262-012-1259-8",
language = "English (US)",
volume = "61",
pages = "1307--1317",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - TriVax-HPV

T2 - An improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

AU - Barrios, Kelly

AU - Celis, Esteban

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse eVects and in most cases are not eVective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is eVective in generating vast numbers of antigen-speciWc T cells in mice capable of persisting for long time periods. Materials and methods We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic eYcacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E749-57, mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. Results TriVax using HPV16-E749-57 induced large and persistent T-cell responses that were therapeutically eVective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6-11-day established tumors. In addition, TriVax induced long-Term immunological memory, which prevented tumor recurrences. The anti-Tumor eVects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon. Conclusions These Wndings indicate that the TriVax strategy is an appealing immunotherapeutic approach for the treatment of established viral-induced tumors. We believe that these studies may help to launch more eVective and less invasive therapeutic vaccines for HPV-mediated malignancies.

AB - Background Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse eVects and in most cases are not eVective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is eVective in generating vast numbers of antigen-speciWc T cells in mice capable of persisting for long time periods. Materials and methods We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic eYcacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E749-57, mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. Results TriVax using HPV16-E749-57 induced large and persistent T-cell responses that were therapeutically eVective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6-11-day established tumors. In addition, TriVax induced long-Term immunological memory, which prevented tumor recurrences. The anti-Tumor eVects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon. Conclusions These Wndings indicate that the TriVax strategy is an appealing immunotherapeutic approach for the treatment of established viral-induced tumors. We believe that these studies may help to launch more eVective and less invasive therapeutic vaccines for HPV-mediated malignancies.

KW - CD8 T cells

KW - Cervical cancer

KW - HPV

KW - PIVAC 11

KW - Peptide vaccines

UR - http://www.scopus.com/inward/record.url?scp=84865748503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865748503&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1259-8

DO - 10.1007/s00262-012-1259-8

M3 - Review article

C2 - 22527249

AN - SCOPUS:84865748503

VL - 61

SP - 1307

EP - 1317

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -